NasdaqGS:SYREBiotechs
How Investors May Respond To Spyre Therapeutics (SYRE) Upsized Equity Raise After Positive SPY001 Phase 2 Data
In mid-April 2026, Spyre Therapeutics completed a US$403.00 million follow-on common stock offering at US$62.00 per share, shortly after reporting positive 12-week Phase 2 SKYLINE data for its ulcerative colitis candidate SPY001, which met its primary endpoint and showed a safety profile consistent with the a4ß7 class.
The decision to expand the offering from a prior US$300.00 million filing and add Jefferies as co-lead underwriter underscores how the SPY001 data have become a central pillar...